Mark Brader

Title: Mark Brader: Innovator in Factor IX Polypeptide Formulations

Introduction

Mark Brader is a notable inventor based in Lexington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of Factor IX polypeptide formulations. With a total of 4 patents to his name, Brader's work has the potential to impact therapeutic approaches for hemophilia.

Latest Patents

Brader's latest patents include innovative formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide. This invention provides methods of administering FIXFBP, which could enhance the efficacy of treatments for patients with Factor IX deficiencies. Additionally, he has developed methods for administering long-acting Factor IX, as well as chimeric and hybrid polypeptides that incorporate Factor IX. These advancements also include methods for producing such polypeptides using cells, showcasing his commitment to improving patient care.

Career Highlights

Brader is currently associated with Bioverativ Therapeutics Inc., where he continues to push the boundaries of research and development in the field of hemophilia treatment. His work is characterized by a focus on creating long-lasting therapeutic solutions that can significantly improve the quality of life for patients.

Collaborations

Throughout his career, Brader has collaborated with esteemed colleagues such as Glenn Pierce and Samantha Truex. These partnerships have fostered an environment of innovation and have contributed to the successful development of his patented technologies.

Conclusion

Mark Brader's contributions to the field of biotechnology, particularly in Factor IX polypeptide formulations, highlight his role as a leading inventor. His work not only advances scientific knowledge but also holds promise for improving therapeutic options for patients with hemophilia.